Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2022-07-12 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 12, 2022. It announces a virtual research and development day event and includes a corporate presentation and a press release as exhibits. The document does not contain detailed financial statements or substantive financial data but rather serves as an announcement of events and filings. The length is 4248 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes current reports like Form 8-K.
2022-07-12 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 16, 2022, by Leap Therapeutics, Inc. The content focuses on the submission of matters to a vote of security holders at the 2022 Annual Meeting of Stockholders, including election of directors, approval of an equity incentive plan, and ratification of the independent auditor. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4115 characters, which is short but contains detailed voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). The primary content is the official results from shareholder votes at the annual meeting, fitting the DVA category with high confidence.
2022-06-16 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2022, by Leap Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2022, and includes a press release as an exhibit. The text explicitly states that the full financial results are in the press release attached as Exhibit 99.1, and the 8-K itself is a current report announcing these results. The document is 4226 characters long, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The Form 8-K is commonly used for earnings releases and other significant events. Therefore, this document is best classified as an Earnings Release (ER).
2022-05-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-05-13 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a company's annual meeting of stockholders. It includes details about the annual meeting, proposals to be voted on, voting instructions, and availability of proxy materials. It is not the annual report itself, nor is it a voting results announcement. The document is clearly a proxy solicitation material, as it provides information to shareholders to solicit their votes for the annual meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement or a report publication notice, but the actual proxy materials or additional materials related to the proxy statement.
2022-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.